Abstract: The present disclosure relates to phosphorylated hexaacyl disaccharide (PHAD) compounds, compositions, and methods for treating or preventing infections.

Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.

Abstract: The invention concerns the field of genetic vaccination, in particular RNA vaccines. The present invention provides an mRNA for use in the treatment and/or prevention of a disease, wherein the mRNA is administered to the epidermis. Furthermore, the invention provides compositions comprising the mRNA for epidermal administration or kits comprising the mRNA for epidermal administration. Moreover, the invention concerns the medical use of the mRNA or compositions comprising the mRNA, wherein the mRNA or compositions comprising the mRNA are administered to the epidermis.

Abstract: Provided herein are methods for one or more of: inhibiting the development of non-alcoholic steatohepatitis (NASH), non-alcoholic liver steatosis (NAFLD), fatty liver disease, liver fibrosis, hepatocellular carcinoma; blocking the biosynthesis of fatty acids and triglycerides; inhibiting de novo lipogeneis. The method comprises administering an effective amount of an agent that interferes with the binding of the estrogen receptor related receptor (NR3B) to a NR3B target to a subject in need thereof.

Abstract: The present invention relates to a liquid mixture or solid mixture, in powder or granules, comprising or, alternatively, consisting of alginic acid and hyaluronic acid, or a salt thereof, for use in the treatment, in particular in the curative treatment, of extraoesophageal symptoms or disorders caused or provoked by gastroesophageal reflux (GERD) or by a partial reflux of gastric contents, such as, for example, the partial upflow of pepsin, hydrochloric acid, gastric juices or acidic gastric vapours from the stomach and wherein said disorders or symptoms manifest themselves in an extraoesophageal region.

Abstract: A method for the delivery of aggrecan precursors to the joint of a subject, comprising the steps of: a) applying a composition comprising one or more aggrecan precursors chosen from the list comprising hyaluronic acid, glucosamine sulfate and/or chondroitin sulfate to the skin of the subject on or near a joint, wherein the composition is applied between the skin and a flexible magnetic film.

Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

Abstract: Disclosed is a composition for alleviating symptoms of atopic dermatitis that contains a high molecular weight poly-gamma-glutamic acid and a low molecular weight poly-gamma-glutamic acid as active components. The composition for improving symptoms of atopic dermatitis inhibits epidermal and transepidermal water loss, improves desquamation (scaling skin), provides an excellent skin soothing effect, and relieves pruritus (itch) caused by dryness, thereby making remarkable improvement of general symptoms of atopic dermatitis.

Abstract: Provided herein are compounds, compositions, and methods for modifying mucus, including modifying mucus using nitric oxide-releasing biopolymers (e.g., NO-releasing chitosan oligosaccharides). In some embodiments, a compound, composition, and/or method of the present invention modifies one or more properties of mucus to increase mucus clearance in a subject and/or prevents the growth or kills one or more pathogens present in mucus of a subject.

Abstract: Disclosed herein are therapeutic polymer gel systems for promoting healing of a wound or surgical site in a subject. The therapeutic polymer gel forms a microporous network and may be applied or injected in a fluid form and annealed or crosslinked after application to the wound or surgical site. The microporous gel may optionally contain various therapeutic agents throughout the therapeutic polymer gel which are released.

Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating spinal cord injury comprising an imidazole-poly(organophosphazene) hydrogel or a pharmaceutically acceptable salt thereof, a method for preventing or treating spinal cord injury, and a food composition for preventing or ameliorating spinal cord injury. The imidazole-poly(organophosphazene) hydrogel of the present disclosure has the effect of regenerating the extracellular matrix (ECM) by filling cystic cavities and can thus be effectively used for the prevention and treatment of spinal cord injury by a simple injection method.

Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.

Abstract: In some aspects, the present disclosure provides compositions comprising an N4-based MMC ligand, a cell targeting group, and a fluorophore or a therapeutic compound comprising a formula: wherein the variables are as defined herein. In some embodiments, these compositions may be used in the imaging techniques or in the treatment of a disease or disorder such as cancer.

Abstract: This invention discloses a pharmaceutical formula for arthritis treatment and/or prevention. The formula contains the following raw materials: a selenium-containing inorganic compound and a zinc-containing inorganic compound. The pharmaceutical formula described herein could be manufactured for topic application and provide a faster and safer treatment for various inflammatory joint pains. Pharmacodynamics results show that the invented pharmaceutical formula can significantly reduce the level of inflammatory cytokines in the joint synovial fluid in arthritis rabbit model, and the formulated ointment can achieve better efficacy compared with Voltaren™ (diclofenac) ointment; therefore the proposed formula has promising clinical application.

Abstract: Stannous fluoride polyol solid solutions combine three complimentary, biochemical mechanisms attributed to Sn++, F? and Polyol, respectively to reduce growth and metabolism of Streptococcus mutans while effecting superior Bioactivity Quotients. The stannous fluoride polyol solid solution particulate compositions of the present invention comprise: (a) stannous fluoride at between about 0.01 and about 0.8% by weight; (b) a polyol at between about 0.1 and about 30% by weight; (c) an astringency neutralizer at between about 0.01 and about 0.4% by weight, where the ratio of astringency neutralizer to stannous fluoride is from between about 0.01 and about 0.2; (d) a mucoadhesive at between about 1.

Abstract: A seal formulation for forming a physical barrier in the teat canal of a non-human animal comprises zinc oxide in a gel base. The seal formulation contains at least 40% by weight of the zinc oxide.

Abstract: The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

Abstract: The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

Abstract: The present disclosure relates to a method for treating cancer including steps as follows. A chemotherapy drug is administered to a subject in need for a treatment of cancer. Then a composition containing a plurality of chimeric antigen receptor expressing cells is administered to the subject, wherein the chimeric antigen receptor expressing cells expresses a chimeric antigen receptor specific to human leukocyte antigen G (HLA-G).

Abstract: The invention provides a method of treating an adult subject having a hematological cancer, comprising administering to the subject selected dosage regimens comprising a plurality of immune effector cells expressing a CAR molecule.

Abstract: Methods and compositions for treating cancer are disclosed. The compositions comprise immune cells pretreated with ponatinib, or immune cells co-administered with ponatinib, where ponatinib promotes survival and anti-cancer cytotoxicity of the immune cells.

Abstract: The present disclosure relates to methods of using engineered cytotoxic T cells comprising a recombinant vector construct that expresses a chimeric antigen receptor to reduce and/or deplete the number of B cells in a subject in order to treat autoimmune diseases, such as lupus.

Abstract: Provided herein are immune cells expressing antigenic receptors, such as a chimeric antigen receptor and a T cell receptor. Further provided herein are methods of treating immune-related disorder by administering the antigen-specific immune cells.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Provided are engineered cells fused with platelet membrane vesicles and capable of specifically targeting a subendothelial site of vascular injury. Also provided are methods of generating a modified cell or extracellular vesicle fused with platelet membrane vesicles or fragments thereof. Further provided are methods for using these engineered cells and vesicles for the treatment of injured tissue accompanied by vascular injury by engraftment with modified cells fused with platelet membrane vesicles. Cells fused with the platelet vesicles can be engineered stem cells such as cardiac or mesenchymal stem cells; the extracellular vesicles fused with the platelet vesicles can be exosomes such as exosomes derived from cardiac or mesenchymal stem cells. The use of the platelet vesicles for targeting sites of vascular injury may also be usefully applied to engineering cells and exosomes that have therapeutic activity for the treatment of vascular injury.

Abstract: Provided herein are methods and compositions for dynamically controlling and targeting multiple arms of the immune system. Some aspects provide mesenchymal stem cells (MSCs) engineered to produce multiple effector molecules. In some instances, each effector molecule modulates a different cell type of the immune system or different functions of a cell. Also provided herein are methods of using the MSCs to treat or alleviate symptoms of inflammatory bowel disease (IBD), for example.

Abstract: Biocompatible hybrid fibrous scaffold, derived from a synthetic polymer and a natural hydrogel, and methods of use thereof in tissue engineering.

Abstract: Embodiments disclosed here provide engineered modified hematopoietic stem cells (HSCs), artificially prostaglandin E2 (PGE2)-stimulated HSCs, compositions comprising these HSCs, methods of using these modified HSCs for treating autoimmune diseases and disorders and for suppressing the immune system. In particular, the engineered modified HSCs or PGE2-stimulated HSCs express the surface marker, programmed cell death-1 ligand 1 (PD-L1).

Abstract: The present invention relates to a method of inducing differentiation into a 3D dopaminergic midbrain organoid using a specific electromagnetic wave. It was specifically identified that the method makes it possible to remarkably improve production efficiency of a dopaminergic neuronal 3D-differentiated organoid, from which symptoms of Parkinson's disease can be effectively alleviated. Thus, it is anticipated that the present invention is capable of making a more fundamental approach and achieving targeted therapies in the treatment of a cranial nerve disease.

Abstract: Provided herein are methods and compositions comprising cardiomyocytes and epicardial cells for the treatment of cardiac disease.

Abstract: The present invention provides a pharmaceutical composition for healing tissue, said pharmaceutical composition containing: adherent cells originating from mesenchymal tissue that has been treated with a physiologically active polypeptide or an LPS; and a pharmaceutically acceptable carrier.

Abstract: Described herein are compositions and methods for treating retinal diseases or disorders using RPE cells.

Abstract: A method of treating cancer includes administering a dose of a chemotherapy agent in combination with a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent. The combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the composition consisting essentially of attenuated Salmonella typhimurium.

Abstract: Compositions and methods are provided for modulating growth of a genetically modified bacterial cell present in a human organ, for modulating growth of a genetically modified bacterial cell in an organ (e.g., gut), for displacing at least a portion of a population of bacterial cells in an organ, and for facilitating gut colonization by a genetically modified bacterial cell. Also provided are genetically modified bacterial cells, e.g., cells that include a heterologous carbohydrate-utilization gene or gene set that provides for the ability to utilize as a carbon source a rare carbohydrate of interest that is utilized as a carbon source by less than 50% of bacterial cells present in a human microbiome.

Abstract: The present invention relates to probiotic compositions and methods of using such compositions. In particular, the present invention provides methods of using Faecalibacterium spp. to increase milk production in animals.

Abstract: The disclosure relates to a therapeutic composition for treating L. monocytogenese infection or L. monocytogenese colonization, the composition including at least one, at least two, at least three, or all of an isolated C. saccharogumia bacteria, an isolated C. ramosum bacteria, an isolated C. hathewayi bacteria, and/or an isolated B. producta bacteria in a formulation suitable for administration to a subject. The disclosure further provides similar compositions lacking an isolated C. saccharogumia bacteria. The disclosure additionally provides methods of treating L. monocytogenes infection or colonization using such compositions.

Abstract: Dietary supplements comprising at least one probiotic and at least one of animal digest, dried brewers yeast, vitamin C; vitamin E, beta carotene, zinc proteinate, manganese proteinate, ferrous sulfate, copper proteinate, calcium iodate, and sodium selenite. The probiotics and other ingredients are present in the supplement in amounts sufficient to enhance the palatability of the probiotics and compositions containing the probiotics, enhance the immune system to augment the beneficial effects of the probiotics, or extend the life of the probiotics.

Abstract: The present invention relates to bacteria and metabolites thereof that are capable of binding to A, B and/or O blood type antigens or which are acid and/or bile tolerant, their use in probiotic compositions and food products, and methods for their selection. The invention also relates to the use of said bacteria and metabolites for the prevention and/or treatment of gastrointestinal disorders.

Abstract: An object of the present invention is to provide a therapeutic composition for preventing, ameliorating, or treating metabolic syndrome. The present invention provides a composition for preventing, ameliorating, or treating metabolic syndrome, which composition contains Lactobacillus plantarum L-137.

Abstract: Disclosed are novel modified viruses comprising recombinant PTEN-Long and methods of using the same for treating cancer.

Abstract: A pharmaceutical combination comprising (i) a replicative oncolytic vaccinia virus and (ii) an immune checkpoint protein inhibitor is provided as well as a kit comprising the pharmaceutical combination and methods for treating and/or preventing cancer.

Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.

Abstract: A preparation containing the mycoparasitic microorganism Pythium oligandrum for the treatment of dermatophytoses and yeast infections on the skin and mucous membranes obtained from a dry mixture containing 0.1 to 99.9% weight mycoparasitic microorganism Pythium oligandrum and 0.1 to 99.9% auxiliary substances, containing at least one component from a group comprising adsorbent, buffer, moisturizer, deodorant and aroma. This preparation contains 1 to 10×106, with preference of 10 to 50, viable cells of the Pythium oligandrum microorganism per 1 ml of aqueous suspension at the site of applying the preparation, whereby the viable cells of the Pythium oligandrum microorganism comprise dormant oospores, encysted zoospores and viable coenocytic mycelium. Different application methods of using the preparation are claimed. Exemplary embodiments show the viability of cells using genetic tests and practical tests conducted under the supervision of dermatologists, stomatologists and veterinarians.

Abstract: A plant-based composition containing an alcohol extract of Tecoma species (e.g. Tecoma stans) and an exogenous carrier and/or excipient. Also provided is a composition including a mixture of three acids, namely corosolic acid, oleanolic acid, and ursolic acid, which can be found in the Tecoma species. Methods of treating skin lesions (e.g. warts, corns, calluses, and umbilical granulomas) and reducing symptoms associated with the skin lesions using such compositions are specified.

Abstract: The present invention provides in methods for reducing or inhibiting DNA damage in a cell. The methods administer compositions of at least a pomegranate polyphenol to reduce or inhibit DNA damage in the cell.

Abstract: The present invention relates to a novel combination comprising an extract of watercress, an extract of Indian cress, and ATP, and to the use of said combination in the field of hair science, more particularly in the treatment or prevention of alopecia.

Abstract: The invention relates to an extract of aerial parts of Maca rich in polyphenols, and also to a composition comprising such an extract and, where appropriate, a suitable excipient. The invention also relates to a process for extracting an extract of aerial parts of Maca rich in polyphenols, and also to the extract that can be obtained by means of said process. The invention also relates to such a composition or such an extract for use thereof in preventing or treating disorders or pathological conditions of the skin, the mucous membranes or the superficial body growths and/or for use thereof in preventing and/or treating vascular disorders. Finally, the invention relates to a cosmetic care process for the skin, the superficial body growths or the mucous membranes, with a view to improving the condition thereof or the appearance thereof, which comprises the administration of such a composition or of such an extract.

Abstract: A Cucumis Sativus L. extract is disclosed herein, which is designed for use in the treatment and/or prevention of enteropathies, particularly of inflammatory origin, in pets, and more particularly enteropathies in dogs.

Abstract: A first embodiment of a composition for treating vitiligo includes Cassia tora powder, Saussurea lappa root powder, Punica granatum L. (pomegranate) peels powder, and Psoralea corylifolia black seed powder. A second embodiment of a composition for treating vitiligo can include Cassia tora powder, Saussurea lappa root powder, Punica granatum L. (pomegranate) peels powder, Berberries (or Berberis) vulgaris root powder, red clay (with trace copper), and Ptychotis verticillata root powder. Topical administration of the first composition followed by UV radiation exposure can facilitate inducing melanogenesis as well as generating ROS. Topical administration of the second composition following the UV radiation exposure can scavenge the ROS generated by the first composition.